Mesenchymal stromal cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice by Yan Li et al.
RESEARCH Open Access
Mesenchymal stromal cell treatment
prevents H9N2 avian influenza virus-
induced acute lung injury in mice
Yan Li1,2†, Jun Xu3†, Weiqing Shi3, Cheng Chen1, Yan Shao1, Limei Zhu1, Wei Lu1* and XiaoDong Han2*
Abstract
Background: The avian influenza virus (AIV) can cross species barriers and expand its host range from birds to
mammals, even humans. Avian influenza is characterized by pronounced activation of the proinflammatory cytokine
cascade, which perpetuates the inflammatory response, leading to persistent systemic inflammatory response
syndrome and pulmonary infection in animals and humans. There are currently no specific treatment strategies for
avian influenza.
Methods: We hypothesized that mesenchymal stromal cells (MSCs) would have beneficial effects in the treatment of
H9N2 AIV-induced acute lung injury in mice. Six- to 8-week-old C57BL/6 mice were infected intranasally with 1 × 104 MID50
of A/HONG KONG/2108/2003 [H9N2 (HK)] H9N2 virus to induce acute lung injury. After 30 min, syngeneic MSCs were
delivered through the caudal vein. Three days after infection, we measured the survival rate, lung weight, arterial blood gas,
and cytokines in both bronchoalveolar lavage fluid (BALF) and serum, and assessed pathological changes to the lungs.
Results: MSC administration significantly palliated H9N2 AIV-induced pulmonary inflammation by reducing chemokines
and proinflammatory cytokines levels, as well as reducing inflammatory cell recruit into the lungs. Thus, H9N2 AIV-induced
lung injury was markedly alleviated in mice treated with MSCs. Lung histopathology and arterial blood gas analysis were
improved in mice with H9N2 AIV-induced lung injury following MSC treatment.
Conclusions: MSC treatment significantly reduces H9N2 AIV-induced acute lung injury in mice and is associated with
reduced pulmonary inflammation. These results indicate a potential role for MSC therapy in the treatment of clinical avian
influenza.
Keywords: Mesenchymal stromal cell, H9N2 avian influenza viruses, Lung injury, Cell therapy
Abbreviations: AI, Avian influenza; AIV, Avian influenza virus; ALI, Acute lung injury; ARDS, Acute respiratory distress
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Background
Infections with avian influenza virus (AIV) strains have
become highly prevalent in poultry worldwide [1–4].
Avian influenza (AI) is a leading cause of morbidity, mor-
tality, and economic loss in many countries. Mammals
can also be infected with several AIV subtypes, including
H5N1, H9N2, H7N7, and H7N3 [5, 6]. In 1997, 18 people
were infected with avian H5N1 influenza virus and six
died, refocusing global attention on the potential role of
AIVs as precursors of human pandemic influenza virus
strains [7, 8]. The H9N2 strain has been isolated from pigs
and humans with influenza-like illnesses in Hong Kong
and mainland China since 1998 [9, 10]. These findings in-
dicate that the AIV can also cross species barriers and ex-
pand its host range from birds to mammals, thus
highlighting the pandemic potential of the H9N2 virus.
Although the H9N2 avian virus subtype is generally
not highly pathogenic for avian species, it has been asso-
ciated with severe morbidity and mortality in poultry
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following coinfection with other pathogens [11, 12].
Recent findings indicate that the H5N1 viruses responsible
for severe human disease contain genetic rearrangements
that include several genes from obtained avian H9N2
viruses [13].
However, despite decades of research, few therapeutic
strategies for clinical AI have emerged, and current
specific treatment options are limited. Treatment of AI
currently still relies on antiviral agents. A recent
Cochrane review reported that antiviral therapies had lit-
tle benefit for severe influenza patients [14, 15]. Further-
more, AI continues to require prolonged mechanical
ventilation in the intensive care unit, and AI-associated
mortality remains high at 30–50 % despite optimal sup-
portive care [3, 16].
The reasons for the high mortality associated with AI
are unknown; the presence of a new viral subtype to which
the human host has no prior immunity cannot totally ex-
plain this phenomenon. AIV is well known to mainly
cause pneumonia, severe acute lung injury (ALI), and
acute respiratory distress syndrome (ARDS) in humans
[17]. A clinically important pronounced activation of the
proinflammatory cytokine cascade perpetuates the inflam-
matory response and may contribute to further tissue
damage and persistence of the systemic inflammatory re-
sponse syndrome, leading to pulmonary infection in both
animals and humans [18, 19]. We therefore hypothesized
that improving immune regulation would benefit the
treatment of AI.
Cell therapies using bone marrow-derived mesenchymal
stromal cells (MSCs) have emerged as potential novel
therapeutic approaches for several diseases [20, 21].
Several studies have shown that both ectogenic and endo-
genic MSCs can migrate into the lung, adopt the pheno-
type of lung cells, and play positive roles in repairing lung
injury, including that caused by ARDS, emphysema, and
idiopathic pulmonary fibrosis [22–24]. Importantly, recent
studies have demonstrated that bone marrow-derived
MSCs can exhibit immunosuppressive properties. In
addition, MSCs have been suggested to be “immune eva-
sive”, and thus protected from rejection, which potentially
permits their use in allotransplantation [25, 26]. MSCs
may also engraft in the injured lung and can even differen-
tiate into lung epithelial cells in vivo [27]. Therefore,
MSCs may be beneficial in the treatment of AI.
The aim of this study was to evaluate the effect of
MSC treatment on lung inflammation and injury in-
duced by H9N2 AIV infection in a murine model.
Methods
Isolation, culture, and characterization of MSCs
MSCs were isolated from the bone marrow of C57BL/6
mice weighing 20–30 g, obtained from the Shanghai
Laboratory Animal Research Center (Shanghai, China)
and maintained under specific pathogen-free conditions.
Bone marrow was flushed from the femurs under aseptic
conditions using DMEM. The collected cells were
washed three times with PBS, resuspended in DMEM
containing 10 % fetal bovine serum and 1 % L-glutamine,
and seeded at 1 × 106 cells/ml into culture flasks. Cells
were maintained in a humidified atmosphere of 95 % air
and 5 % CO2 at 37 °C. Nonadherent cells were discarded
after 48 h and the culture medium changed every 3–4
days thereafter. Cells were harvested when they reached
approximately 90 % confluency and were diluted 1:2 or
1:3 at each passage. MSCs used in all in vivo experi-
ments were between passages 3 and 10.
Fluorescence-activated cell sorting analysis
Passage 3–10 MSCs were analyzed for the following
markers: CD34, CD45, CD73, CD79, CD90, and CD105.
A total of 1 × 105 cells were incubated with each
fluorescence-conjugated primary antibody at 37 °C for 2
h in the dark. After three PBS washes, cells were proc-
essed by flow cytometry (BD FACSCalibur) and data
were analyzed using Cell Quest software. Antibodies
used were: anti-mouse CD34, CD45, and CD79 (Santa
Cruz Biotechnology Inc.); anti-mouse CD73, CD90, and
CD105 (BioLegend, San Diego, CA), and all of the anti-
bodies were labeled with FITC.
Differentiation of MSCs
Passage 5 MSCs were differentiated into adipocytes, chon-
drocytes, and osteocytes using the Mouse Mesenchymal
Stem Cell Functional Identification Kit (R&D, USA) to
prove their ability to differentiate into multiple mesenchy-
mal lineages. Methods were according to the procedures
of protocol; briefly, MSCs were plated at 1 × 104/well in
24-well plates and incubated in α-MEM containing 10 %
fetal bovine serum and 1 % L-glutamine until they reached
approximately 50–70 % confluency for differentiation.
Cells were cultured in adipogenic, osteogenic, or chondro-
genic media for 10–21 days before being prepared for
lineage-specific immunocytochemistry stains. Adipocytic
differentiation was confirmed by staining with FABP4, dif-
ferentiation to osteocytes was confirmed by staining with
osteopontin, and differentiation to chondrocytes was con-
firmed by staining with collagen II as previously described.
Briefly, cells were washed with PBS and fixed in 4 % para-
formaldehyde in PBS for 20 min. The cells were perme-
abilized and blocked with 0.5 ml PBS containing 0.3 %
Triton X-100 and 1 % BSA at room temperature for 30
min. After blocking, the cells were incubated with Goat
Anti-mouse FABP4, osteopontin, or Sheep Anti-mouse
Collagen II antibody working solution for 1 h at 37 °C;
they were then washed and incubated with Alexa 555 la-
belled Rabbit Anti-Goat secondary antibody in the dark
for 60 min at room temperature. Images of the stained
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cells were obtained by using a phase fluorescence micro-
scope (Axio Observer, Zeiss, Germany).
Murine H9N2 infected mice of H9N2 AIV-induced acute
lung injury
A/Hong Kong/2108/2003 [H9N2 (HK)] AIV was kindly
provided by Prof. Zheng Xing (Medicine School, Nanjing
University). To assess pathological changes induced by
H9N2 AIV, 6-week-old female SPF C57BL/6 mice were
housed in microisolator cages in the animal facility of
the Jiangsu Provincial Center for Disease Prevention and
Control under conditions of negative pressure and venti-
lated with HEPA-filtered air.
A total of 95 C57BL/6 mice were divided into seven
groups: A: controls (n = 10); B: MSCs (n = 10); C: H9N2
infected mice + physiological saline (n = 15); D: H9N2
infected mice +McCoy (n = 15); E: H9N2 infected mice +
MSCs (n = 15); F: H9N2 infected mice + physiological saline
(n = 15); G: H9N2 infected mice +MSCs (n = 15). Groups
B–D had MSCs, McCoy, or saline administered 30 min
following viral infection induction, while groups E and F
were administered 1 day after. To induce lung injury in
H9N2-infected mice, diethyl ether was used to anesthetize
the mice and 1 × 104 MID50 (Median Infective Dose) of A/
HONG KONG/2108/2003 [H9N2 (HK)] H9N2 AIV dis-
solved in 10 μl sterile physiological saline was administered
intranasally. Control mice were treated with noninfectious
allantoic fluid of the equivalent dilution. Thirty minutes
after H9N2 AIV challenge, physiological saline, McCoy, or
syngeneic MSCs (1 × 105 cells; 100 μl total volume) were
slowly infused into each mouse via the caudal vein. Naive
mice (without H9N2 AIV instillation) were injected with
saline or MSCs to serve as controls for any inflammatory
response that might result from the injected MSCs. Mice
were humanely killed by ether anesthesia followed by
percutaneous left ventricular bleeding 3 days after MSC
treatment and their tissues were harvested for analysis.
McCoy was used as a negative control.
Virus titration in lung of mice
Virus titration in lung homogenate of three mice per
group was detected to quantify the infection level. Tissues
were collected and homogenized in cold phosphate-
buffered saline on day 3 after treatment. Clarified homog-
enates were titrated for viral infectivity in embryonated
chicken eggs from initial dilutions of 1:2. Viral titers were
expressed as mean log10 EID50/ml ± SD (1 MID50 is
around 1 × 103 EID50).
Survival rate and lung weight
Three days after treatment, the survival rate was observed
for each experimental group. In addition, the upper right
lung lobes were weighed before and after oven desiccation
at 70 °C to determine the lung wet:dry weight ratio. Lung
wet:dry weight ratio = weight of the wet lung/weight of
the dry lung; relative lung weight (%) = weight of the
whole wet lung/body weight × 100 %. These were used as
indicators of lung edema.
Histopathology
Lung tissue samples of three mice per group (one cross
section of the right lower lobe, one of the right mid lobe,
and one of the right upper lobe) were fixed in 4 % parafor-
maldehyde, embedded in paraffin, and cut into 4-μm thick
sections. Sections were stained with hematoxylin and
eosin, and observed using an optical microscope. All lungs
were uniformally inflated and fixed in the same way. The
average interalveolar septum thickness was quantified in a
blinded fashion by measuring the thickness of all septae
along a crosshair placed on each image (at least 100 septae
were measured per animal). Lung injury score was
observed for quantification of the lung damage; briefly,
images were evaluated by an investigator who was blinded
to the identity of the slides (WCL) according to a previ-
ously defined scoring system [28]. The grading system was
as follows: 0, minimal damage; 1, mild damage; 2, moder-
ate damage; 3, severe damage; and 4, maximal damage.
Arterial blood gas analysis
Five mice from each group were anesthetized with di-
ethyl ether on day 3 postinoculation. Arterial blood sam-
ples (100 μl) of lightly anesthetized mice spontaneously
breathing room air were withdrawn into a heparinized
syringe by percutaneous left ventricular sampling. Blood
gas analysis was immediately performed with an i-STAT
300 blood gas/electrolytes analyzer (Abbott, USA).
Cytokine measurement
Concentrations of the chemokines granulocyte-macrophage
colony-stimulating factor (GM-CSF), monocyte chemo-
attractant protein (MCP-1), keratinocyte chemoattractant
(KC), macrophage inflammatory protein-1α (MIP-1α), and
monokine induced by IFN-γ (MIG) and the inflammatory
cytokines interleukin (IL)-1α, IL-6, IL-10, tumor necrosis
factor alpha (TNF-α), and interferon (IFN-γ) in bronchoal-
veolar lavage fluid (BALF) and serum (five mice from each
group) were measured 3 days after H9N2 infection using
the Mouse Cytokine Magnetic 20-Plex Panel (Invitrogen) by
Luminex 100 (Bio-Rad, USA).
BALF of mice was collected immediately following sac-
rifice. Briefly, the lungs were lavaged three times with a
total volume of 1.0 ml physiological saline (4 °C) in the
chest cavity opened by midline incision. The rate of recov-
ery of BALF was not less than 90 % for all of the animals
tested.
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Protein expression
Expression of CD14, TLR4, ERK, and JNK protein in lung
tissue was measured 3 days after H9N2 infection using
Western blotting. Lung tissue proteins were obtained
from the right lower lungs of mice in each group. Briefly,
tissues were lysed in ice-cold extraction buffer containing
protease inhibitor cocktail (Roche) and then centrifuged at
12,000 g for 30 min; the protein concentration in the
supernatant was determined using BCA assays. Proteins
were separated using 10 % SDS-polyacrylamide gel
electrophoresis and electrophoretically transferred to
polyvinylidene fluoride (PVDF) membranes using
Fig. 1 Flow cytometric analysis of MSCs. Isolated MSCs do not express CD45, CD34, or CD79 (a–c), but do express C105, CD73, and CD90 (d–f).
Grey lines represent a non-stained control, red lines represent specific antibody staining
Fig. 2 Differentiation of passage 5 MSCs into osteocytes, adipocytes, and chondrocytes. Fluorescence microscopy images of osteogenic differentiation
(osteopontin staining of undifferentiated MSCs (a) and differentiated osteocytes (b)), adipogenic differentiation (FABP4 staining of undifferentiated MSCs (c),
and differentiated adipocytes (d)), and chondrogenic differentiation (collagen II of undifferentiated MSCs (e) and differentiated chondrocytes (f))
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standard procedures. The membranes were blocked at
37 °C for 1 h in phosphate-buffered saline (PBS) con-
taining 0.05 % (vol/vol) Tween 20 and 5 % (wt/vol)
non-fat milk for 1 h at RT. Membranes were then in-
cubated in primary antibody at a 1:500 dilution in
PBSTM (PBS containing 0.05 % (vol/vol) Tween 20
and 0.1 % (wt/vol) non-fat milk) for 3 h at RT and
then washed three times for 5 min each in PBSTM.
Membranes were then incubated with the appropriate
horseradish peroxidase (HRP)-conjugated anti-species
secondary antibodies (Boster, Wuhan, China) for 1 h
at RT and then washed in PBSTM as described above.
Immunoreactive protein bands were detected using an
Odyssey Scanning System (LI-COR, Inc., Lincoln, NE,
USA). Ratios for the protein of interest (POI) were
expressed relative to GAPDH in the same sample as
a loading control. The primary antibodies rabbit anti-
CD14, TLR4, ERK, JNK, and GAPDH were obtained
from Santa Cruz (USA).
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health.
The protocol was approved by the Committee on the
Ethics of Animal Experiments of the University of
Minnesota (approval no. A9089). All surgery was per-
formed under sodium pentobarbital anesthesia, and all
efforts were made to minimize suffering.
Statistical analysis
Data are expressed as the mean ± standard deviation (S.D.).
All calculations and statistical analyses were performed
using SPSS for windows version 13.0 (SPSS Inc., Chicago,
IL, USA). One-way ANOVA followed by Dunnett’s t test
was used to analyze differences between groups. P < 0.05
was regarded as statistically significant.
Results
Highly pure MSCs can be isolated from murine bone
marrow
After approximately 2 weeks of culture, isolated MSCs
had expanded significantly and exhibited evident plastic
adherence. After three to four passages, MSCs exhibited a
homogeneous fibroblast-like, spindle-shaped morphology.
FACS analysis demonstrated that passage 3–10 MSCs did
not express CD34, CD45, or CD79 (Fig. 1a–c), but did ex-
press CD73, CD90, and CD105 (Fig. 1d–f ). These data in-
dicate that the cultured cells were of mesenchymal origin
and of a high purity. Passage 5 MSCs readily differentiated
into adipocytes, osteocytes, or chondrocytes when incu-
bated in differentiation medium, confirming their pluripo-
tent potential (Fig. 2).
Virus titration in the lungs of mice
H9N2 viral infection resulted in high viral titers in the
lungs; the viral titers of the H9N2 infected mice +
physiological saline group, H9N2 infected mice +McCoy
group, and H9N2 infected mice +MSCs group exceeded
6.0 log10 EID50/ml (Fig. 3) on day 3 post-infection.
Survival rate and lung weight
Three days after infusion of MSCs, we observed that the
survival rate of mice in the H9N2 infected mice +MSCs
group was higher than that of the H9N2-infected mice
groups; the survival rate of the H9N2 infected mice +
MSCs group was 100 %, whereas that of the H9N2-
infected mice groups were approximately 80 % (3 deaths
out of 15 mice in the H9N2 infected mice + physiological
saline group and 2 deaths out of 15 mice in the H9N2
infected mice +McCoy groups) (Fig. 4).
Mean relative lung weights and lung wet:dry weight
ratios were significantly higher (p < 0.05) in H9N2-
infected lungs versus control mice and significantly
Fig. 3 Virus titration in the lungs of mice. Mean viral titers based on
three mice per group are expressed as log10 EID50 per milliliter ± SD
Fig. 4 The survival rate of mice in different experimental groups 3 days
post-treatment. Kaplan-Meier curves are shown for mice in different
groups. MSCs could improve survival in experimental AI mice. See text
for definition of groups A–G
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lower (p < 0.05) in mice treated with H9N2 +MSCs ver-
sus those of the H9N2-infected groups (Fig. 5).
Histopathology
Lung sections from mice in the H9N2 infected mice +
physiological saline group and H9N2 infected mice +
McCoy group displayed similar histopathological patterns
consistent with severe diffuse pneumonia and characterized
by inflammatory cellular infiltration, numerous poly-
morphonuclear leukocytes and macrophages in interstitial
spaces, interstitial and alveolar edema, and hemorrhage.
Diffuse pneumonia with severe alveolar damage was ob-
served throughout the entire lung (Fig. 6c and d). Adminis-
tration of MSCs (H9N2 infected mice +MSCs) reduced
airspace inflammation and improved lung histopathology.
Lung structure was less abnormal than in the H9N2 in-
fected mice + physiological saline group, suggesting that
therapy with MSCs is protective against H9N2-induced
lung injury (Fig. 6e). The severity of lung injury was also
assessed using a semiquantitative histopathological scoring
system that evaluated lung injury in four categories: alveolar
septae, alveolar hemorrhage, intra-alveolar fibrin, and intra-
alveolar infiltrates. Although treatment with MSCs tended
to reduce lung injury scores (Fig. 7), the observed differ-
ences did not reach statistical significance.
Arterial blood gas analysis
Arterial blood gas parameters in the different experi-
mental groups are shown in Table 1. In the H9N2-
infected mice, the partial pressure of arterial oxygen
Fig. 5 Effect of MSCs on lung weights of mice in comparison to control mice. a Lung wet:dry weight ratios and b relative lung weight.
*Response that is significantly different from the control (p < 0.05).▲Response that is significantly different from the H9N2 infected mice (p < 0.05).
See text for definition of groups A–G
Fig. 6 Histological evaluation of the therapeutic potential of MSCs on AIV-induced lung injury in mice. Lung pathology of mice in different experimental
groups 3 days post-treatment (hematoxylin and eosin, 100× magnification). a Control group, b MSC group (lungs of control and MSC groups showed a
normal aspect), c H9N2 infected mice + physiological saline group, d H9N2 infected mice +McCoy group (diffuse pneumonia and severe alveolar injury
were observed), e H9N2 infected mice +MSCs group (MSC transplantation reduced lung injury). f H9N2 infected mice+ Physiological saline administer 1
day following viral infection induction (Severe diffuse pneumonia and extensive alveolar damage). g H9N2 infected mice+MSCs administer 1 day following
viral infection induction (MSC transplantation reduced lung inflammation and injury)
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(PaO2) was significantly lower, while the partial pressure
of arterial carbon dioxide (PaCO2) was significantly
higher, and the values for saturation of arterial oxygen
(SaO2) and pH were slightly lower. Compared with the
H9N2 infected mice + physiological saline and H9N2 in-
fected mice +McCoy groups, mice in the H9N2 infected
+MSCs group had significantly higher PaO2, signifi-
cantly lower PaCO2, and slightly higher (but still statisti-
cally significantly different) SaO2 and pH values. These
results indicate that most of the H9N2 AIV infected
mice developed severe hypoxemia, and that MSCs effect-
ively protected against functional pulmonary injury.
Cytokine measurements
Chemokines
Three days after H9N2 infection, the concentrations of
GM-CSF, MCP-1, KC, MIP-1α, and MIG were measured
in both BALF and serum. The concentrations of all che-
mokines were increased in BALF and serum (Fig. 8) in
the H9N2 infected mice + physiological saline group. In
contrast, the concentrations of chemokines were much
lower in the H9N2 infected mice +MSCs group.
Inflammatory cytokines
The concentrations of IL-1α, IL-6, IL-10, TNF-α, and
IFN-γ were measured in BALF and serum 3 days after
H9N2 infection. In the H9N2 infected mice + physio-
logical saline group, the concentrations of these inflamma-
tory cytokines were significantly increased in both BALF
and serum (Fig. 9). In contrast, the concentrations were
significantly lower in the H9N2 infected mice +MSCs
group.
Protein expression
Three days after H9N2 infection, the expression of
CD14, TLR4, ERK and JNK protein in the lung tissue
was measured. In the H9N2-infected mice, the expres-
sion of CD14, TLR4, ERK, and JNK protein in lung tis-
sue was significantly increased compared with the
control group. Mice in the H9N2 infected +MSCs group
had significantly decreased ERK and JNK expression
compared with the H9N2 infected mice + physiological
saline and H9N2 infected mice +McCoy groups. The ex-
pression of CD14 and TLR4 in mice in the H9N2 in-
fected +MSCs group tended to be lower, although not
significantly so (Fig. 10).
Discussion
The present study demonstrated that MSCs exert a
beneficial therapeutic effect on H9N2 AIV-induced lung
injury in a murine model; treatment with MSCs results
in improvements in both pulmonary inflammation and
lung tissue organization. These findings have potentially
important implications for the treatment of AI, which is
an important clinical problem characterized by high pa-
tient morbidity and mortality.
Fig. 7 Lung injury score of mice in different experimental groups 3
days post-treatment. Data are represented as mean ± standard error
of the mean; n =6 per group. *Response that is significantly different
from the control (p < 0.05). ▲Response that is significantly different
from the H9N2 infected mice (p < 0.05). See text for definition of
groups A–G
Table 1 Effect of H9N2 avian influenza virus (AIV) and mesenchymal stromal cells (MSCs) on arterial blood gas analysis of mice
Groups pH PO2 (mmHg) PCO2 (mmHg) SO2
A: Control (allantoic fluid; n = 10) 7.23 ± 0.032 90.8 ± 6.43 38.5 ± 1.66 92.7 ± 0.73
B: MSCs (1 × 105 MSCs; n = 10) 7.29 ± 0.031 88.2 ± 5.51 37.9 ± 1.11 93.8 ± 1.02
C: H9N2-infected mice (1 × 104 MID50 H9N2AIV; n = 15) 6.62 ± 0.286 46 ± 4.17* 65.34 ± 2.55* 64.82 ± 1.63*
D: H9N2-infected mice + MSCs (1 × 104 MID50 H9N2AIV + 1 × 10
5 McCoy; n = 15) 6.71 ± 0.257 48.2 ± 5.11* 64.32 ± 1.98* 68.15 ± 1.75*
E: H9N2-infected mice +MSCs (1 × 104 MID50 H9N2AIV + 1 × 10
5 MSCs;
n = 15, 30 min following infection)
6.84 ± 0.613 68 ± 5.76*▲ 50.05 ± 1.09*▲ 78.47 ± 1.54*▲
F: H9N2-infected mice (1 × 104 MID50 H9N2AIV; n = 15) 6.97 ± 0.375 46 ± 4.35* 66 ± 3.34* 65 ± 2.44*
G: H9N2-infected mice +MSCs (1 × 104 MID50 H9N2AIV + 1 × 105 MSCs;
n = 15, 1 day following infection)
6.77 ± 0.712 60 ± 3.35*▲ 52.39 ± 4.13*▲ 75.89 ± 2.44*▲
*Response that is significantly different from the control (p < 0.05)
▲Response that is significantly different from the H9N2-infected mice (p < 0.05)
PaCO2 partial pressure of arterial carbon dioxide, PaO2 partial pressure of arterial oxygen, SaO2 saturation of arterial oxygen
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Fig. 8 Levels of chemokines in bronchoalveolar lavage fluid (BALF) and serum. Concentrations of the chemokines granulocyte-macrophage
colony-stimulating factor (GM-CSF), monocyte chemoattractant protein (MCP-1), keratinocyte chemoattractant (KC), macrophage inflammatory
protein-1α (MIP-1α), and monokine induced by IFN-γ (MIG) in each group were measured using Luminex in bronchoalveolar lavage fluid and serum.
Groups as legend. Group comparisons were made using one-way ANOVA with Dunnett’s post hoc test. *p< 0.05; **p< 0.01; n= 6 mice per group. MSC
mesenchymal stromal cell
Fig. 9 Levels of inflammatory cytokines in bronchoalveolar lavage fluid (BALF) and serum. Concentrations of the inflammatory cytokines interleukin
(IL)-1α, IL-6, tumor necrosis factor alpha (TNF-α), and interferon gamma (IFN-γ), and of IL-10 were measured using Luminex in bronchoalveolar lavage
fluid and serum. Groups as legend. Group comparisons were made using one-way ANOVA with Dunnett’s post hoc test. *p < 0.05; **p < 0.01; n = 6
mice per group. MSC mesenchymal stromal cell
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Avian H9N2 viruses have been widespread in domestic
poultry in Asian countries since the mid-1990s, with a
mortality ranging from 5–30 % [29, 30]. Many studies
have shown that H9N2 viruses can cause upper re-
spiratory tract illnesses in humans. This indicates that
the virus has evolved to cross the species barrier and
is capable of infecting humans, bypassing intermediate
hosts.
H9N2 viruses can activate the innate immune re-
sponse. A hallmark of pulmonary infiltration associated
with AI is the presence of infiltrating leukocytes [31, 32].
Leukocyte migration is directed largely by chemokines,
and the inter-relationship of early-response cytokines,
adhesion molecules, and chemokines orchestrates the re-
cruitment of neutrophils into the lungs [33]. In most
studies, cytokines have been described as forming an in-
flammatory “cascade” or “network” in patients [30, 34].
Lung injury may be a direct consequence of this inflam-
matory response.
Adult stem cells or progenitor cells are being evaluated
for the treatment of a number of diseases that currently
have limited or no treatment options [35, 36]. Marrow-
derived stem cells are hypothesized to be the source of
lung regeneration and repair. An alternative source are ex-
ogenous stem/progenitor cells, delivered into the lung ei-
ther intravenously via the trachea or by direct injection.
Recently, many studies have confirmed that MSCs can
engraft in the injured lung [37–39] and can even
differentiate into lung epithelial cells in vivo. MSCs may
also exhibit immunosuppressive properties, suggesting
“immune-privilege”, and may even have certain immune
regulation functions [40–42]. Therefore, MSCs may, in
their own right, have beneficial effects in ALI.
Our data showed that H9N2 viral infection dramatically
increases the expression of chemokines, including GM-
CSF, MCP-1, KC, MIP-1α, and MIG, in both BALF and
serum. However, MSC treatment decreases the expression
of these chemokines. We also showed that MSC-treated
mice have significantly reduced levels of some inflamma-
tory cytokines (IL-1α, IL-6, TNF-α, and IFN-γ) and a
corresponding increase in anti-inflammatory cytokines
(IL-10). It is believed that IL-1α, IL-6, TNF-α, and IFN-γ
play important roles in the development of ALI [43].
These results are consistent with several previous studies.
For example, in Mei’s study, treatment with MSCs alone
significantly reduced LPS-induced acute pulmonary in-
flammation in mice [39]. Importantly, our in vivo experi-
mental results suggest that the administration of MSCs
can greatly improve the hypoxemia and histopathological
changes of lung injury induced by H9N2 AIV infection.
The data indicate that administration of MSCs results in a
marked increase in survival rates, primarily due to a de-
crease in ALI. These results are not consistent with the
findings of Lam et al. [44], who reported that MSC ther-
apy fails to improve outcomes in experimental HIN1 in-
fluenza. We speculate that this might be a consequence of
Fig. 10 Western blotting analyzed the expression of TLR4-related protein in the lung tissue after MSC transplantation for 3 days. a Expression of
CD14, TLR4, ERK, and JNK were evaluated by immunoblotting using specific antibodies. GAPDH is used as the control. 1: controls, 2: MSCs, 3: H9N2, 4:
H9N2 +McCoy, 5: H9N2 +MSCs, 6: H9N2 + Physiological saline (1 day following) 7: H9N2 +MSCs (1 day following). b Responses were quantified by
densitometry and normalized to the expression of GAPDH. Densitometry data are shown as mean ± SD. *Response that is significantly different from
the control (p < 0.05). ▲Response that is significantly different from the H9N2 infected mice (p < 0.05)
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different pathogenic characteristics of different influenza
viruses. It is known that avian influenza virus infection
can lead to a “cytokine storm”. In consequence, the host
cellular response may be different from that with H1N1
influenza virus infection.
We have, therefore, demonstrated that MSC-based cell
therapy can attenuate the inflammatory reaction and in-
jury in the lungs caused by H9N2 AIV exposure, as well
as by reducing lung histopathological changes. These
beneficial effects may be mediated by the downregula-
tion of chemokines such as GM-CSF, MCP-1, KC, MIP-
1α, and MIG, leading to the downregulation of inflam-
matory cytokines such as TNF-α, IL-1α, IL-6, and IFN-γ.
Our findings provide further support for a prominent
role of TLR4-dependent immune regulation in acute
lung injury therapy. The quantity of stem cells used in
our study was 1 × 105. This is much less than used by
Wang et al. [45]. We did not find an obvious stem cell
niche in the lung tissue of mice. Therefore, we deduce
that the immune regulation function of stem cells is via
a paracrine mechanism.
On the other hand, it is possible that MSCs may be in-
volved in the early stages of carcinogenesis through
spontaneous transformation. In addition, it has been
suggested that MSCs can modulate tumor growth and
metastasis, although this remains controversial and
poorly understood. Interestingly, different studies have
reported contradicting findings, with some finding that
MSCs promote tumor growth and others that they in-
hibit tumor growth. Therefore, the role of MSCs in avian
influenza infection requires ongoing surveillance.
Conclusions
Our results suggest that MSC-based therapy can reduce
inflammatory lung injury and pulmonary vascular perme-
ability. This may provide a novel strategy for the treatment
of AIV-induced lung injury through improving tissue re-
pair and protecting against inflammation. Further investi-
gations into the application of MSC-based cell therapy
may give new hope for patients with AIV-induced ALI.
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